Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ravulizumab

ravulizumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ravulizumab

13 trials tracked of ravulizumab: 11 in phase 3 or 4 and 9 with published results. The most-cited published study has 383 citations.

13Trials tracked
11Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 1 Phase 3 10 Phase 2 1 Phase 1 1
  1. Phase 3 ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Completed · 383 cited
  2. Phase 3 Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Completed · 244 cited
  3. Phase 3 Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Completed · 224 cited
  4. Phase 3 Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment Completed · 150 cited
  5. Phase 3 ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed · 129 cited
  6. Phase 3 Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Completed · 65 cited
Show 7 more trials
  1. Phase 3 Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Completed · 25 cited
  2. Phase 3 A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria Completed · 13 cited
  3. Phase 3 An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Completed · 10 cited
  4. Phase 4 Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Completed
  5. Phase 3 Study of Ravulizumab in Pediatric Participants With HSCT-TMA Completed
  6. Phase 2 Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed
  7. Phase 1 Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mechanistic-driven diagnosis and therapy shift focus from platelet counts to underlying pathophysiology of thrombocytopenia
Hematology Sys. Review
Mechanistic-driven diagnosis and therapy shift focus from platelet counts to underlying pathophysiology of thrombocytopenia New Framework Offers Precise Treatment for Low Blood Platelets
This systematic review synthesizes the multidimensional pathogenesis of thrombocytopenia across five axes including production, immune-media…
A new diagnostic framework moves beyond simple blood counts to identify the specific cause of low platelets for more precise treatment.
Frontiers Sep 29, 2026
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
Oncology Meta-analysis
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
Apr 14, 2026
Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient
Rheumatology
Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient Doctors report a single case where ravulizumab treated a rare blood disorder after COVID-19 in a kidney transplant patient
A case report describes a 75-year-old kidney transplant recipient who developed complement-mediated thrombotic microangiopathy (CM-TMA) trig…
A kidney transplant patient with COVID-19 improved after doctors treated a rare blood disorder with ravulizumab, showing age shouldn't block…
Frontiers Mar 31, 2026